Regeneron Pharmaceuticals and BioNTech side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Regeneron Pharmaceuticals | BioNTech |
|---|---|---|
| Phase 1 | Regeneron Pharmaceuticals: 9 of its 44 programs at phase 1 and 4 more — sign in to see them all | BioNTech: 4 of its 24 programs at phase 1
|
| Phase 2 | Regeneron Pharmaceuticals: 16 of its 44 programs at phase 2
and 11 more — sign in to see them all | BioNTech: 16 of its 24 programs at phase 2
and 11 more — sign in to see them all |
| Phase 3 | Regeneron Pharmaceuticals: 15 of its 44 programs at phase 3
and 10 more — sign in to see them all | BioNTech: 3 of its 24 programs at phase 3
|
| Approved, new studies | Regeneron Pharmaceuticals: 4 of its 44 programs at approved, new studies
| BioNTech: 1 of its 24 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals14 readouts · 4 phase 3 | · | Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion
| Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion
| Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion
| · | · |
| BioNTech4 readouts · 1 phase 3 | BioNTech, Nov ’26: 1 program whose next study reaches primary completion
| · | BioNTech, Jan ’27: 1 program whose next study reaches primary completion
| · | · | BioNTech, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | BioNTech, Jun ’27: 1 program whose next study reaches primary completion
| · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Regeneron Pharmaceuticals
New programs 6
- REGN20566phase 1 · first study · Nov 13 · Obesity
- REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
- REGN13089phase 2 · first study · Oct 2
- REGN24493phase 1 · first study · Sep 30 · Graves Disease
- REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
- ALN-6457phase 2 · first study · Sep 16 · Dementia
Reached a new phase 2
- olatorepatidephase 3 · Oct 19 · Obesity
- ALN-CIDEBphase 3 · Sep 28 · Non-alcoholic Fatty Liver Disease
Study stopped 0
None
Primary completion later 6
- odronextamabphase 3 · Feb 2028 → Feb 2028 (+1 mo) · moved Nov 12 · NCT06091254
- cemiplimabphase 2 · Oct 2029 → Oct 2030 (+12 mo) · moved Nov 10 · NCT06848088
- fianlimabphase 2 · Oct 2029 → Oct 2030 (+12 mo) · moved Nov 10 · NCT06848088
- fianlimabphase 3 · Jul 2026 → Jan 2027 (+6 mo) · moved Nov 10 · NCT05608291
- garetosmabphase 3 · Dec 2028 → Jul 2030 (+19 mo) · moved Oct 8 · NCT07559513
- mibavademabphase 2 · Aug 2027 → Jan 2028 (+5 mo) · moved Oct 1 · NCT07235917
BioNTech
New programs 3
- BNT3211phase 2 · first study · Nov 16
- BNT3219phase 1 · first study · Oct 19
- BNT3210phase 2 · first study · Oct 15
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 2
- pumitamigphase 3 · Jan 2027 → May 2027 (+4 mo) · moved Oct 22 · NCT06616532
- pumitamigphase 3 · Dec 2028 → Apr 2029 (+4 mo) · moved Oct 14 · NCT06712355
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Regeneron Pharmaceuticals | BioNTech |
|---|---|---|
| Carcinoma, Non-Small-Cell Lungboth · compare here | Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs
Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search | BioNTech in Carcinoma, Non-Small-Cell Lung: 2 programs
Their studies: BioNTech’s studies of Carcinoma, Non-Small-Cell Lung in search |
| Prostatic Neoplasmsboth · compare here | Regeneron Pharmaceuticals in Prostatic Neoplasms: 2 programs Their studies: Regeneron Pharmaceuticals’ studies of Prostatic Neoplasms in search | BioNTech in Prostatic Neoplasms: 1 program
Their studies: BioNTech’s studies of Prostatic Neoplasms in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Regeneron Pharmaceuticals | BioNTech |
|---|---|---|
| PDCD1 | cemiplimabrule | Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317rule |
| TNFRSF9 | Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505rule | Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.